Trial Profile
Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Histamine glutarimide (Primary)
- Indications Influenza virus infections; Respiratory tract infections; Viral infections
- Focus Therapeutic Use
- Sponsors Pharmenterprises
- 27 Feb 2018 New trial record